ArticleAnnals of biomedical engineering2025
Ex Vivo Assessment of Transcatheter Edge-to-Edge Treatment Performance After Pathology Recurrence in Functional Tricuspid Regurgitation.
Article in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional tricuspid regurgitation (FTR) is closely associated with right ventricular (RV) dysfunction and pulmonary hypertension (PH), both of which contribute to increased morbidity and mortality in patients undergoing tricuspid valve repair or replacement. The biomechanical interplay between these factors remains complex, with conflicting evidence on the effects of edge-to-edge repair (TEER) on RV morphology and function. This study aimed to assess the acute impact of increased pulmonary pressure and RV dilation on TEER performance using an ex vivo pulsatile flow mock loop. A custom-designed clip, replicating state-of-the-art TEER devices, was tested on porcine heart samples under simulated FTR conditions with varying degrees of RV dilation and PH.Results demonstrated that the clip significantly improved valve coaptation, increasing transvalvular systolic pressure and reducing regurgitant flow. However, elevated PH and severe RV dilation compromised its effectiveness, leading to increased regurgitation and a higher risk of pathology recurrence. Statistical analysis identified PH as the primary driver of hemodynamic deterioration, whereas RV dilation predominantly influenced annular morphology. These findings suggest that while TEER provides initial hemodynamic benefits, its efficacy may be limited in advanced FTR cases with progressive RV dysfunction and PH. Further research is needed to evaluate long-term outcomes. Nonetheless, this ex vivo approach allowed for the isolation of key biomechanical mechanisms, offering valuable insights into the structural and functional relationships underlying disease progression.
Indexed as
Identifiers
40555876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.